Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by webpiloton Apr 04, 2011 10:18am
234 Views
Post# 18381066

More Good News

More Good News
Asmost have seen, there is good news regarding the distribution ofVivimind. The new area of the world covered by the new partner is alarge portion of the Middle East.  Please note in the new agreement thatin addition to supplying Vivimind at a predetermined price are theroyalties of 15-17%.  The company is doing a great job, soon Vivimindwill be available all over the world, except of course in the US.  What ajoke that is.  We are now awaiting the start of distribution inCanada.  I believe that it was supposed to begin on April 1.  But thereseems to be a delay, I don't think that it is a problem with supply butrather the hammering out of the final terms of the contract.  It would be greatif there are royalties with this contract.  We shall see.  I don'tthink that companies all over the world are agreeing to sell or sign acontract to distribute Vivimind unless there is solid evidence that it works andthat there has been tremendous feedback from customers that have been onVivimind for a long time.

Everyday we see in the news thatthere is no one product or prescription that can help to protect the brain.  Well, I myopinion these articles are written by people with an agenda.  The onlyagenda that Bellus has is to help people.  These authors should instead writeabout the one single product that actually works to promote a healthybrain.

Another thing that I notice is that Bellus has decided tocontinue to rent reduced space at their present location.  If you remember,The company was looking for a new location after they agreed to abuyout of the lease that they were operating under.  This will save plentyof capital.  As part of the negotiations with the landlord, shares wereissued in March and there was a second payment due on April 7 tocomplete the contract.  Well since the company is now agreeing to stay,but with a much smaller area and much less rent, will the landlord nowforgive this second payment of stock or money thus saving additionaldilution.  That will be great if this is in fact what has happened.Perhaps the landlord will see that this is the best course of action atthis time.
 
Bullboard Posts